1. Field of the Invention
The present invention relates to an apparatus and method for the exposure of blood to light as a medical treatment. More specifically, the invention involves the controlled exposure of a stream of blood to ultraviolet (UV) light under conditions that effect a salubrious change in the blood.
2. Description of the Related Art
Light is well known as an effective medical treatment. In the nineteenth century, it was shown that light could inhibit bacteria growth and kill some microorganisms. In 1903, Niels R. Finsen won the Nobel Prize for Medicine by treating certain skin conditions (e.g., tuberculosis) with light. Before the advent of antibiotics, physicians began to use UV light to treat a variety of infections, many of which were ill defined at the time.
In the 1920's, 1930's, and 1940's, researchers began to develop devices for the exposure of blood to UV radiation, and reported positive results. For example, U.S. Pat. Nos. 1,683,877, 2,308,516, and 2,309,124 to L. A. Edblom and E. K. Knott are considered by some to be the key, early developments in the field, which was known as the Knott HEMOIRRADIATOR®. Although the mechanism of this device and the treatment were little understood at the time, the conclusion was that UV blood irradiation therapy enhanced the body's immune response. These references disclosed an extra-corporeal system in which whole blood was drawn, mixed with an anti-coagulant, pumped through a chamber where it was exposed to UV light between 1800 and 4000 angstroms—with a concentration or peak at 2540 angstroms—and then returned to the body. Although the first invention disclosed blood flow through two needles, Knott found a single needle arrangement to be speedier for his closed loop system. The exposure chamber included a transparent window through which the light source would shine onto the flowing blood. The chamber was designed to agitate the blood as it flowed by this flat window, so that more cells and bacteria would be exposed to the UV light. The '516 patent refined the device and advised users that exposure of more than 5 seconds could be detrimental.
Historically, the introduction of antibiotics and vaccines reduced the interest in the use of light for medical treatment. Nevertheless, development continued throughout the twentieth century. Most of the later developments seemed to be characterized by inventions that involved: (a) the separation and exposure of a portion or component of the blood (e.g., U.S. Pat. No. 4,613,322 to Edelson), (b) the addition of a compound or photo-active agent to the blood (e.g., U.S. Pat. No. 4,737,140 to Lee), or (c) both (e.g., U.S. Pat. Nos. 4,321,919, 4,398,906, 4,464,166, 4,612,007, 4,613,322, 4,683,889, 4,684,521 all to Edelson). A few references addressed improvements in the design of the exposure chamber and the blood transport system. As in the Knott design, all these developments retained the need for anti-coagulant treatment, and focused on large or macro scale improvements in exposure.
In U.S. Pat. No. 5,150,705, Stinson disclosed a cylindrical exposure chamber comprising a central UV light source, effective for treating transplant cells, located within a UV transparent cylinder, and UV transparent tubing for carrying a cellular suspension. The tubing is wrapped helically about the cylinder to promote consistent exposure of the tubing to the UV source. Such a macro scale arrangement was intended to maximize the tube's efficiency in capturing UV emissions from a cylindrical source. However, depending on the overall fluid characteristics, the micro scale blood flow relative to the tube could be stratified by density, leading to uneven exposure of the blood.
Another example of an evolutionary configuration of an exposure chamber is shown in U.S. Pat. No. 6,312,593, to Petrie. The Petrie device discloses a chamber that features a series of baffle plates and transverse protuberances to produce a Bernoulli distortion in the blood flow, creating desirable agitation. In fact, the Knott design contemplated agitation of the blood; this invention used the energy of the fluid flow reacting to a transverse disturbance to cause a pressure gradient, thereby forcing blood at a lower depth to move upward. As the blood moved up, it had a greater chance of being exposed to the flat transparent window that Knott introduced. The transverse aspect of the disturbance required sufficient longitudinal flow to generate enough disturbance for the desired exposure.
Accordingly it is an object of the present invention to provide a method for treating blood which provides improved exposure of blood to UV light.
Another object of the present invention is to provide a method for treating blood which increases the likelihood that each blood cell is exposed to the proper amount of UV light.
Another object of the present invention is to provide a method for treating blood which reduces the amount time blood must be exposed to UV light.
Another object of the present invention is to provide a method for treating blood which reduces the likelihood of cellular separation and hemolysis.
Yet another object of the present invention is to provide a method for treating blood which treats blood rapidly.
Yet another object of the present invention is to provide a method for treating blood which does not result in coagulation of the blood.
Finally, it is an object of the present invention to accomplish the foregoing objectives in a simple and cost effective manner.
The present invention addresses the foregoing problems, as well as other problems, by providing a chamber for exposing a stream of blood flowing through the chamber to ultraviolet light to destroy microorganisms and to stimulate the immune system. The chamber includes an ultraviolet-light-transparent blood flow path having an inlet port and an outlet port. The blood is induced to flow in a spiral within the blood flow path located within the chamber and is exposed to an ultraviolet light source. The blood flow path can be formed from any ultraviolet-light-transparent material such as polystyrene, polypropylene or quartz. If desired, the blood flow path can be formed from a plurality of materials, such that different portions absorb a different wavelength of UV light or, alternatively, one or more filters can be used to regulate the exposure of the blood flow path to ultraviolet rays. The spiral movement in the blood is caused by, for example, threaded walls on the internal surface of the blood flow path or by a static mixer. Preferably, a vacuum is formed between the ultraviolet light source and the blood flow path. Any gaps between the ultraviolet light source and the blood flow path can be filled with an optically transparent material such as quartz. The ultraviolet light source can be one or more light bulbs, preferably emitting light within at least the ultraviolet A range. If appropriate, the ultraviolet light can be pulsed such that the blood is exposed to the ultraviolet light on a discontinuous basis.
The following detailed description is of the best presently contemplated modes of carrying out the invention. This description is not to be taken in a limiting sense, but is made merely for the purpose of illustrating general principles of embodiments of the invention.
A device for the exposure of blood to light can be built that produces a controlled, safe, and rapid exposure of blood to specific emissions, thereby inducing improved immune response. The present invention achieves this through a simplified blood flow path.
The exposure chamber design enhances control over the exposure of the blood to ultraviolet light. The exposure chamber includes a blood flow path 10, such as a modified tube, or channel crafted from a UV transparent material, such as transparent polystyrene or polypropylene. These materials permit blood flow in a variety of macro configurations or arrangements during the period of exposure to UV light, so long as each red blood cell is exposed to the emissions for the desired time. In the event that an otherwise desirable transparent material is found to absorb an important wavelength of UV light, then the flow path could be constructed of segments of varying light absorption characteristics (i.e., different transparent materials). Alternatively, filters may be employed to expose the blood to selected wavelengths. A particularly preferred design for the macro configuration within the exposure chamber 20 is a double helix type geometry as shown in
Consistent exposure of all or most of the subject cells is safer and more efficient than variable, partial exposure. A spiral or helical path of tubing on a macro scale has been tried in order to enable a tube to embrace a generally cylindrical UV source and to capture efficiently its emissions. That design concentrated on efficient use or capture of the UV emissions by overall configuration of the tubing. In contrast, as shown in
The desired internal spiral flow of blood within blood flow path 10 may be achieved in a variety of ways. This is not the same thing as a macro scale orientation or potentially helical twisting of a flow path 10. Instead, this is a channel or tube featuring means to induce an internal or micro scale spiral flow; the blood flow path 10 may feature means for inducing a spiral flow of the blood such as internally threaded walls, a spiral blade, or an internal Kenics® static mixer. Kenics® static mixers are a class of mixers that use static structural elements 12, such as vanes situated within a flow channel for alternating or changing fluid flow. An example of a static mixer is shown in U.S. Pat. No. 3,286,992. Some versions of these mixers, as shown in
Preferably, for the macro scale design, as illustrated in the simple example of
The light source 30 should provide the desired spectral emissions, with exposure appropriate to the flow and configuration of the chamber. The UV light source 30 can be a single UV light bulb or a plurality of UV light bulbs. Preferably, a light source 30 emitting UVA light is used. If a light bulb, or combination of light bulbs, which emits UVB or UVC light in addition to UVA light is used, one or more filters 33 can be used so that the blood is exposed to the desired UVA light, as shown in
The design of the exposure chamber, the pulse frequency and intensity, and the volumetric flow rate are preferably considered together for optimal control. Many whole blood designs seek an individual red cell exposure period of about ¼ to ½ seconds, while also avoiding cellular separation and hemolysis. The volume of the exposure chamber will depend on the pulse frequency, desired exposure time, and volumetric flow rate. A sample of approximately 250 milliliters of blood (or 1.5 milliliters per kilogram of body weight) may be treated at a time. In a design with a volumetric blood flow rate of approximately 1 milliliter per second, the device could process the entire sample through the exposure chamber in a period of four minutes and ten seconds.
In a particularly preferred embodiment, the exposure chamber and blood flow path can be made as disposable items. This embodiment has the added benefits of eliminating the need to sterilize these items and the concern of transmission of infectious diseases.
An additional feature of the micro scale approach is reduced time of treatment. In the present invention, the spiral flow within the exposure chamber promotes controlled, thorough, and rapid exposure. Prior designs that operated more slowly face the problem of coagulation of the blood. Typical approaches to compensate for this problem are the addition of heparin, or the inclusion of other anti-coagulant measures. The rapidity and control of the present invention offers an alternative. Preferably, the blood should be drawn from one point and returned to the patient at a different point, as shown in
In an alternate embodiment of the present invention, the blood can be separated into four portions once it is removed from the patient: erythrocytes, leukocytes, platelets and blood plasma. In this embodiment, each portion would be separately exposed to ultraviolet light for treatment and then reintroduced to the patient separately or collectively.
This contemplated arrangement for the exposure of blood to light may be achieved in a variety of configurations. While there has been described what are believed to be the preferred embodiment of the present invention, those skilled in the art will recognize that other and further changes and modifications may be made thereto without departing from the spirit of the invention, and it is intended to claim all such changes and modifications as fall within the true scope of the invention.
The present application claims priority from U.S. patent application Ser. No. 10/462,344 filed Jun. 16, 2003, which claims benefit of U.S. Provisional Application Ser. No. 60/388,798, filed Jun. 14, 2002.
Number | Date | Country | |
---|---|---|---|
60388798 | Jun 2002 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10462344 | Jun 2003 | US |
Child | 11497789 | Aug 2006 | US |